GlassScriptPhysician profile
Enver Akalin
NPI 1407885205
$100,954.46
in general payments reported to CMS, 2019-2025
17 companies · $28K in 2025
The $28K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,667 · 2020: $106 · 2021: $44K · 2022: $1,523 · 2023: $8,779 · 2024: $12K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $33K · Travel and Lodging: $14K · Food and Beverage: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $32,867.00 |
| Travel and Lodging | $14,325.30 |
| Food and Beverage | $799.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immucor, INC. | $49,500.00 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27,005.66 | 2021-2025 | Gammagard Liquid |
| Otsuka America Pharmaceutical, INC. | $8,944.71 | 2024 | |
| Apellis Pharmaceuticals, INC. | $4,602.00 | 2025 | |
| Mallinckrodt Enterprises LLC | $4,262.20 | 2019 | |
| Gilead Sciences, INC. | $3,201.50 | 2019 | |
| Calliditas Therapeutics US INC. | $2,527.64 | 2023-2024 | Tarpeyo |
| Abbvie INC. | $336.82 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $289.68 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $97.08 | 2023 | |
| Veloxis Pharmaceuticals, INC. | $58.92 | 2019-2021 | |
| Kamada LTD. | $47.99 | 2025 | |
| Genzyme Corporation | $41.19 | 2019 | |
| Janssen Pharmaceuticals, INC | $39.07 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Enver Akalin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.